Dynavax announced positive topline results from Part 1 of its Phase 1/2 trial of Z-1018, a novel shingles vaccine candidate.
Z-1018 demonstrated robust immune responses and favorable tolerability profile compared to Shingrix.
The company selected the optimal dose of Z-1018 for advancement to Part 2 of the trial in older adults.
Robust Immune Responses
Z-1018 showed a 100% humoral vaccine response rate at the selected dose.
Favorable Tolerability Profile
Z-1018 exhibited lower post-injection reactions compared to Shingrix.
Aiming for Best-in-Class Profile
Dynavax aims to disrupt the shingles vaccine market dominated by one product.
- The positive data marks a significant milestone for Dynavax's shingles vaccine program.
- Plans are underway to initiate Part 2 of the trial in older adults to further de-risk the program.
- Z-1018's innovative approach could potentially disrupt the multi-billion-dollar shingles vaccine market.
Dynavax's Z-1018 vaccine has shown promising results and a potential to challenge the current market leader, offering a best-in-class profile.